Cyclerion Therapeutics (CYCN) Return on Assets (2019 - 2025)

Cyclerion Therapeutics (CYCN) posted quarterly Return on Assets of 0.0% for Q4 2025, up 3.01% quarter-over-quarter from 0.0% in Q3 2025.

Cyclerion Therapeutics (CYCN) Return on Assets (2019 - 2025) Analysis & Trends

Cyclerion Therapeutics' Return on Assets history runs 7 years deep, the most recent figure standing at 0.0% for Q4 2025.

In Q4 2025, Return on Assets changed N/A year-over-year to 0.0%; the TTM figure through Dec 2025 stood at 0.0% (changed N/A YoY), while the FY2023 annual figure was 0.0%, up 1.0% from the prior year.
Return on Assets for Q4 2025 stood at 0.0%, up from 0.0% in the prior quarter.
The five-year high for Return on Assets was 0.01% in Q2 2024, with the low at 0.02% in Q1 2023.
The 5-year median for Return on Assets is 0.01% (2021), against an average of 0.01%.
The sharpest annual moves came in 2024 and 2025: Return on Assets grew 3 bps in 2024, then declined 2 bps in 2025.
Cyclerion Therapeutics' Return on Assets stood at 0.01% in 2021, then plunged by 72 bps to 0.02% in 2022, then surged by 131 bps to 0.01% in 2023, then soared by 145 bps to 0.01% in 2024, then sank by 132 bps to 0.0% in 2025.
Business Quant data shows CYCN's Return on Assets at 0.0% in Q4 2025, 0.0% in Q3 2025, and 0.0% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.81 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	86.52 Bn	78.52 Bn	3.93 Bn	0.00%
3	Argenx Se	65.30 Bn	60.11 Bn	1.37 Bn	-
4	Moderna	59.18 Bn	54.04 Bn	52.00 Mn	0.00%
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.77 Bn	28.46 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn	0.00%
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.16 Bn	26.32 Bn	-	0.00%
10	Cyclerion Therapeutics	12.71 Mn	9.47 Mn	-	0.00%

Download Data